Ong-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- BRCA1/2 Mutation
- Sponsor
- Hanyang University Seoul Hospital
- Enrollment
- 4010
- Locations
- 1
- Primary Endpoint
- Recurrence-free survival
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients in breast cancer patients with BRCA 1/2 mutations.
Detailed Description
The purpose of study is to assess the oncologic safety of BCS in patients carrying BRCA1/2 mutations by comparing long-term outcomes with mastectomy. The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients. By providing insights into the feasibility of BCS for patients with BRCA1/2 mutations, the investigators aim to present evidence to aid in surgical decision-making for the care of these patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary invasive breast cancer who underwent BCS or mastectomy
- •Received a BRCA1/2 mutation test
Exclusion Criteria
- •Patients with de novo metastasis
- •Pregnancy-associated breast cancer
Outcomes
Primary Outcomes
Recurrence-free survival
Time Frame: Duration from diagnosis until the development of recurrence up to 10year
Any form of disease recurrence
Distant recurrence-free survival
Time Frame: Duration from diagnosis until the development of recurrence up to 10year
Recurrence in a distant organ
Locoregional recurrence-free survival
Time Frame: Duration from diagnosis until the development of recurrence up to 10year
Recurrence in breast or chest wall and/or regional lymph nodes